Renaissance Technologies LLC increased its position in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Free Report) by 72.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 979,300 shares of the company’s stock after purchasing an additional 412,700 shares during the period. Renaissance Technologies LLC owned approximately 1.40% of Bicycle Therapeutics worth $4,544,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of BCYC. GSK plc purchased a new position in Bicycle Therapeutics in the fourth quarter worth about $10,829,000. Schroder Investment Management Group purchased a new stake in shares of Bicycle Therapeutics during the fourth quarter valued at approximately $3,976,000. Woodline Partners LP purchased a new stake in shares of Bicycle Therapeutics during the first quarter valued at approximately $3,088,000. Birchview Capital LP grew its holdings in shares of Bicycle Therapeutics by 200.5% during the fourth quarter. Birchview Capital LP now owns 462,700 shares of the company’s stock valued at $3,276,000 after buying an additional 308,700 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Bicycle Therapeutics by 156.5% during the first quarter. Millennium Management LLC now owns 453,428 shares of the company’s stock valued at $3,850,000 after acquiring an additional 276,671 shares in the last quarter. 86.15% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,905 shares of the stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total value of $25,214.35. Following the transaction, the chief executive officer owned 605,408 shares of the company’s stock, valued at approximately $2,585,092.16. This represents a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 9,977 shares of company stock worth $42,702 in the last three months. 22.00% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
View Our Latest Stock Analysis on Bicycle Therapeutics
Bicycle Therapeutics Stock Performance
Shares of BCYC opened at $3.97 on Friday. The firm has a market cap of $277.15 million, a PE ratio of -1.45 and a beta of 1.55. The firm has a fifty day simple moving average of $4.14 and a two-hundred day simple moving average of $4.84. Bicycle Therapeutics PLC Sponsored ADR has a 1-year low of $3.74 and a 1-year high of $9.16.
Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.14). The firm had revenue of $0.63 million for the quarter, compared to the consensus estimate of $4.22 million. Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. As a group, research analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -2.23 EPS for the current fiscal year.
About Bicycle Therapeutics
Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.
Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.
Featured Stories
- Five stocks we like better than Bicycle Therapeutics
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Want to see what other hedge funds are holding BCYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Free Report).
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
